Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung Cancer
Journal Title: Journal of Integrative Oncology - Year 2017, Vol 6, Issue 2
Abstract
Introduction: Lung cancer is responsible for the highest mortality caused by malignant solid tumors. Chemotherapy remains one of the most important modality of treatment. Methods: This retrospective study analyzed the records of 42 patients’ treatment with pemetrexed, used in second, third and fourth line chemotherapy for advanced non-squamous non-small cell cancer (NSCLC). Kaplan Meier curve was used for calculation of overall survival. Results: The median overall survival in the second-line was 10 months and in third- and fourth-line was 6.5 months. Discussion: We discuss the similar study with pemetrexed in mono-chemotherapy or combination, study with similar results. Also we make a reference to the new therapy with best results but with much higher cost and effective only for a part of patients. Conclusions: This result and other results presented in similar studies encourage us to recommend pemetrexed in the third and fourth line chemotherapy for well-selected patients.
Authors and Affiliations
Alexandru Calin Grigorescu
Keywords
Related Articles
- EP ID EP348465
- DOI 10.4172/2329-6771.1000187
- Views 61
- Downloads 0
Nurses’ Knowledge and Perceptions of Advance Care Planning, an Ethical Responsibility
Discussions around advance care planning (ACP) do not mean making decisions about what to do at the end of life, but how to cope with disease and treatment. Studies suggest that HPs and patients are ambivalent when talki...
The Chernobyl and It’s Long Term Consequence: Clinical Cases of Leukemia
The Chernobyl accident that occurred 30 years ago was one of the worst nuclear disasters ever. Although it’s effects have been the subject of several articles, the role of its repercussions in the etiology of hematologic...
Febrile Neutropenia Risk with Adjuvant Docetaxel and Cyclophosphamide (TC) Chemotherapy Regimen in Two Brazilians Cancer Centers
Introduction: In selected patients diagnosed with Breast Cancer (BC), adjuvant chemotherapy might reduce local and systemic recurrence risk, as well as cancer death rate. The combination of Docetaxel and Cyclophosphamide...
Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung Cancer
Introduction: Lung cancer is responsible for the highest mortality caused by malignant solid tumors. Chemotherapy remains one of the most important modality of treatment. Methods: This retrospective study analyzed the re...
Second Primary Neoplasms: A Clinico-Pathological Analysis from a Sub Himalayan Cancer Centre in India
Background: There is a lifetime risk of developing another de novo malignancy in diagnosed cancer patients. Detection of new primary has increased due to advances in both diagnostic and treatment modalities. This article...